Verastem’s (VSTM) Buy Rating Reiterated at HC Wainwright
Verastem (NASDAQ:VSTM – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $18.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 237.27% from the stock’s previous [...]